Benitec Biopharma Inc.

NasdaqCM BNTC

Benitec Biopharma Inc. Price to Earnings Ratio (P/E) on January 14, 2025: -11.55

Benitec Biopharma Inc. Price to Earnings Ratio (P/E) is -11.55 on January 14, 2025, a -1,415.78% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Benitec Biopharma Inc. 52-week high Price to Earnings Ratio (P/E) is -0.73 on February 14, 2024, which is 93.70% above the current Price to Earnings Ratio (P/E).
Benitec Biopharma Inc. 52-week low Price to Earnings Ratio (P/E) is -14.81 on December 31, 2024, which is -28.14% below the current Price to Earnings Ratio (P/E).
Benitec Biopharma Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -4.77.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqCM: BNTC

Benitec Biopharma Inc.

CEO	Dr. Jerel A. Banks M.D., Ph.D.
IPO Date	June 24, 2014
Location	United States
Headquarters	3940 Trust Way
Employees	16
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

Key trends

Past 5 years